The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| DSGN | +0.71% | N/A | N/A | -86% |
| S&P | +16.23% | +94.45% | +14.22% | +70% |
Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small molecule therapeutic candidates (GeneTACs) designed to directly address the underlying basis of genetic disease. The company was founded by Pratik Shah and Aseem Z. Ansari on December 18, 2017 and is headquartered in Carlsbad, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.15M | -0.7% |
| Market Cap | $191.31M | 1.1% |
| Market Cap / Employee | $3.36M | 0.0% |
| Employees | 57 | 0.0% |
| Net Income | -$19.08M | -61.8% |
| EBITDA | -$21.42M | -43.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $19.70M | -56.9% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.10M | -43.4% |
| Short Term Debt | $0.84M | 11.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -25.78% | -8.4% |
| Return On Invested Capital | -19.39% | -15.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$14.53M | -27.2% |
| Operating Free Cash Flow | -$14.44M | -28.3% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.17 | 1.38 | 0.90 | 0.84 | 19.56% |
| Price to Tangible Book Value | 1.17 | 1.38 | 0.90 | 0.84 | 19.56% |
| Enterprise Value to EBITDA | -3.30 | -6.44 | 0.42 | 1.06 | -77.06% |
| Return on Equity | -17.8% | -19.1% | -22.6% | -26.8% | 47.84% |
| Total Debt | $2.52M | $2.33M | $2.14M | $1.95M | -28.01% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
